| Literature DB >> 26917593 |
Davide Corti1, John Misasi2, Sabue Mulangu2, Daphne A Stanley2, Masaru Kanekiyo2, Suzanne Wollen3, Aurélie Ploquin2, Nicole A Doria-Rose2, Ryan P Staupe2, Michael Bailey2, Wei Shi2, Misook Choe2, Hadar Marcus2, Emily A Thompson2, Alberto Cagigi2, Chiara Silacci4, Blanca Fernandez-Rodriguez4, Laurent Perez4, Federica Sallusto4, Fabrizia Vanzetta5, Gloria Agatic5, Elisabetta Cameroni5, Neville Kisalu6, Ingelise Gordon2, Julie E Ledgerwood2, John R Mascola2, Barney S Graham2, Jean-Jacques Muyembe-Tamfun6, John C Trefry3, Antonio Lanzavecchia7, Nancy J Sullivan8.
Abstract
Ebola virus disease in humans is highly lethal, with case fatality rates ranging from 25 to 90%. There is no licensed treatment or vaccine against the virus, underscoring the need for efficacious countermeasures. We ascertained that a human survivor of the 1995 Kikwit Ebola virus disease outbreak maintained circulating antibodies against the Ebola virus surface glycoprotein for more than a decade after infection. From this survivor we isolated monoclonal antibodies (mAbs) that neutralize recent and previous outbreak variants of Ebola virus and mediate antibody-dependent cell-mediated cytotoxicity in vitro. Strikingly, monotherapy with mAb114 protected macaques when given as late as 5 days after challenge. Treatment with a single human mAb suggests that a simplified therapeutic strategy for human Ebola infection may be possible.Entities:
Mesh：
Substances：
Year: 2016 PMID： 26917593 DOI： 10.1126/science.aad5224
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728